Lynn Hassman, MD PhD

Uveitis Dr, Ocular Immunology Nerd, Let’s turn scRNA-Seq into Precision Medicine for Uveitis

[Waggoner Lab @LabWaggoner]

Compositional variation in eye-infiltrating immune cells distinguishes human uveitis subtypes
Congrats @LUveitis fellow @uva_bims alum!
https://t.co/X38v62bWX9
@iScience_CP

[Lynn Hassman, MD PhD @LUveitis]

@MACattackLab @WashUDPS Congratulations! Well deserved.

[Lynn Hassman, MD PhD @LUveitis]

@jonykipnis Love this and how it must have ruffled so many feathers!

[Lynn Hassman, MD PhD @LUveitis]

@SaligramaLab @WUSTLmed @SitemanCenter This would be amazing here at WashU!

[Lynn Hassman, MD PhD @LUveitis]

@DGlaucomflecken Stop contracting with UHC for our health insurance.

[Lynn Hassman, MD PhD @LUveitis]

@EdmundTsuiMD @NatEyeInstitute @NIH @UCLASteinEye @DohenyEye @dgsomucla @UveitisSociety @YoungUveitis Congrats!

[Lynn Hassman, MD PhD @LUveitis]

@EricSuhler @UveitisSociety @YoungUveitis Should be illuminating!

[Lynn Hassman, MD PhD @LUveitis]

Opportunity of a lifetime to do cutting-edge research that is changing patient care.

[Lynn Hassman, MD PhD @LUveitis]

Proving that retina docs do pay attention to the cornea!

[Apte Lab @ApteLab]

Very excited to share our new work on corneal epithelial stem cells! Fist bump to first author @linjosephb, student of the @WUSTLmstp.

https://t.co/h0Q4meU9N9

[Ophthalmology @AAOjournal]

Ocular manifestations of ROSAH syndrome caused by variants in ALPK1: optic disc elevation, uveitis and retinal dystrophy. #uveitis #RetinalDystrophy @NatEyeInstitute @NHGRI @NIH https://t.co/oPF5IaBTIO

[Lynn Hassman, MD PhD @LUveitis]

Wow

[Lynn Hassman, MD PhD @LUveitis]

Congratulations to an all-star physician-scientist!

[AUS @UveitisSociety]

Congratulations to Phoebe Lin, MD, PhD who was recently selected for the Academy's Leadership Development Program (LDP) XXIV, Class of 2023.

@aao_ophth #ophthalmology

[Lynn Hassman, MD PhD @LUveitis]

Open position in a great lab!

[Gregory Wu @MS_ResearchDoc]

Please consider a post-doc position in my lab! We have lots of fun. More information here: https://t.co/FrQ6MV00GL

[Lynn Hassman, MD PhD @LUveitis]

@jonas_kuiper @Nature @CapstoneH2020 From Black Death to White Dots

[Lynn Hassman, MD PhD @LUveitis]

@jonykipnis @theNAMedicine Congratulations!

[Schultze Lab @LabSchultze]

Are you an immunologist & want to dive into the omics world? Then this might be a good start!
Super excited to share our guide to systems-level immunomics, online now in @NatImmunol https://t.co/KeDDagArfV
Congratulations to our very own @LorenzoBonaguro @jsschrepping @urealtomek

[Edmund Tsui, MD @EdmundTsuiMD]

If you're heading to #aao2022 make sure to check out our LIVE #aao2022podcast recording @ the Tech Pavilion on Sunday Oct 2, from 1:30-2:30PM CST w/ Dr. Nisha Acharya!

In the meantime, check out the archive of all our past #OphthalmologyJournal podcasts!

https://t.co/jjCkVURRw3

[Apte Lab @ApteLab]

Best U.S. cities for new grads to start a career https://t.co/bci4j7PAyc

[Michael F. Chiang, MD @NEIDirector]

(1/2)
See this video abstract by @CKozyckiMD (@NIAIDTraining) and @NatEyeInstitute physicians Laryssa Huryn & @ShilpaKodati about ROSAH syndrome (new autoinflammatory disease with retinal dystrophy & optic disc edema).

@ARD_BMJ paper (video at bottom): https://t.co/KRe3PgDkio

[Julian Segan @JulianSegan]

FDA approves TYK2 inhibitor deucravacitinib for moderate-severe plaque PSO based on POETYK studies

⚠️Cruicially they have avoided the dreaded JAKi black box warning for MACE and cancer, despite AE profile looking similar to JAKi

Trials ongoing in PsA and SLE. Watch this space!